Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

21.07.2017 | review | Ausgabe 5/2017

Spektrum der Augenheilkunde 5/2017

Neovascular age-related macular degeneration in Austria

Expert review and introduction to the TargetAMD approach

Zeitschrift:
Spektrum der Augenheilkunde > Ausgabe 5/2017
Autoren:
PD Dr. Ulrike Stolba, Siamak Ansari-Shahrezaei, Stefan Hagen, Martin Stattin, Silvia Schmid, Martina Kropp, Nina Harmening, Gabriele Thumann, TargetAMD Group

Summary

Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years of age in developed countries. It is estimated that the projected number of people with AMD will be 196 million worldwide by the year 2020, increasing to 288 million by 2040. Of these patients, 10–20% suffering from the fast progressing neovascular form of the disease (nAMD) account for 90% of all cases of severe vision loss. In fact, AMD is responsible for 8.7% of all cases of blindness worldwide. These numbers indicate the substantial burden of the disease. The WHO estimates that 246 million people worldwide currently have low vision and 39 million are blind. A literature (Medline) and Internet research was performed to better understand the prevalence of AMD and how health care could be prepared to cope with it in the future. In 2015, there were 90,010 intravitreal injections (IVI) in Austrian hospitals and primary care units. In 2016, this number rose to >100,000 IVI as the applications increase by approx. 15–20% every year. Since health insurances do not refund IVI in primary care, these services are channeled toward clinical wards, causing overcrowded waiting rooms and dissatisfied patients. Despite this high number of IVI in Austria, real-life data show that the number of IVI given today is not sufficient to keep visual acuity on a steady level. Therefore, new and long-acting treatment options are needed to end the burden for clinics and patients and to increase treatment efficiency by simplified protocols. Herein, a potential new gene-therapeutic approach using nonviral vectors and somatic pigment epithelial cells to overcome the imbalance of pigment epithelium-derived factor and vascular endothelial growth factor in nAMD is described.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2017

Spektrum der Augenheilkunde 5/2017Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

11.10.2017 | CME | Ausgabe 11/2017

Saisonale allergische Konjunktivitis

06.10.2017 | Leitlinien, Stellungnahmen und Empfehlungen | Ausgabe 11/2017

Stellungnahme des BVA und der DOG zu physikalischen Therapieformen des trockenen Auges

Stand Juli 2017

06.10.2017 | Video plus | Ausgabe 11/2017

Aphake Artisan/Verisyse-Intraokularlinsen als retropupillare Implantate

Videobeitrag

04.10.2017 | Leitlinien, Stellungnahmen und Empfehlungen | Ausgabe 11/2017

Stellungnahme des BVA, der DOG und der RG zur Lasertherapie von Drusen bei altersabhängiger Makuladegeneration (AMD)

Stand August 2017